Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer-Reference-Cited by-同舟云学术

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Published:2018-12-27 Issue:3 Volume:68 Page:517-527
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Chiappori Alberto A.,Williams Charles C.,Gray Jhanelle E.,Tanvetyanon Tawee,Haura Eric B.,Creelan Ben C.,Thapa Ram,Chen Dung-Tsa,Simon George R.,Bepler Gerold,Gabrilovich Dmitry I.,Antonia Scott J.

Funder

National Institutes of Health

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-018-2287-9.pdf

Reference44 articles.

1. Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, Olivier M (2016) TP53 Variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 37:865–876. https://doi.org/10.1002/humu.23035

2. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53